Biogen (BIIB) Cash from Operations (2009 - 2026)

Biogen's Cash from Operations history runs 18 years deep, the most recent figure standing at 448900000.0 for Q2 2026.

• In Q2 2026, Cash from Operations rose 178.99% year-over-year to 448900000.0; the TTM figure through Jun 2026 stood at 2878800000.0 (up 36.0% YoY), while the FY2025 annual figure was 2204600000.0, down 23.33% from the prior year.
• Cash from Operations for Q2 2026 stood at 448900000.0, down from 645500000.0 in the prior quarter.
• The five-year high for Cash from Operations was 1272500000.0 in Q3 2025, with the low at 175000000.0 in Q4 2022.
• The 5-year median for Cash from Operations is 532550000.0 (2024), against an average of 505888888.89.
• The sharpest annual moves came in 2022 and 2024: Cash from Operations sank 120.88% in 2022, then surged 5987.2% in 2024.
• Biogen's Cash from Operations stood at 175000000.0 in 2022, then jumped by 107.14% to 12500000.0 in 2023, then soared by 5987.2% to 760900000.0 in 2024, then sank by 32.72% to 511900000.0 in 2025, then declined by 12.31% to 448900000.0 in 2026.
• Business Quant data shows BIIB's Cash from Operations at 448900000.0 in Q2 2026, 645500000.0 in Q1 2026, and 511900000.0 in Q4 2025.